2Rabe KF, Hurd S, Anzueto A,et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease:GOLD executive summary [ J ]. Am J Respir Crit Care Med, 2007,176:532-555.
3Agusti AG. COPD, a multicomponent disease: implications for management[ J]. Respir Med ,2005,99:670-682.
4Hogg JC, Chu F, Utokaparch S ,et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease [ J ]. N Eng J Med ,2004,350:2645-2653.
5Parr DG, White A J, Bayley DL, et al. Inflammation in sputum relates to progression of disease in subjects with COPD:a prospective descriptive study [ J ]. Respir Res,2006,7 : 136.
6Vaghi A, Berg E, Liljedahl S, et al. In vitro comparison of nebulised budesonide( Pulmicort Respules) and beclomethasone dipropionate ( Clenil per Aerosol) [ J]. Pulm Pharmacol Ther,2005 ,18 :151-153.
7Mahais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulised budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease:a randomized controlled trial [ J ]. Am J Respir Crit Care Med,2002,165 : 698-703.
2GOLD Executive Committee[DB/OL].Guidelines:Global Strategy for Diagnosis,Management,and Prevention of COPD,November 2006[2006-11-18].http://www.goldcopd.com/Guidelineitem.asp? l1 =2-12 = 1&intId =989.
3Celli BR,MacNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper.Eur Respir J,2004,23:932-946.
4Celli BR,Cote CG,Marin JM,ct al.The body mass index,airflow obstruction,dyspnea and exercise capacity index in chronic obstructive pulmonary disease.N Engl J Med,2004,350:1005-1012.
